Research links weight loss medications like Ozempic and Zepbound to certain serious eye conditions.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Some of the most common peptides for weight loss are glucagon-like peptide 1 (GLP-1) receptor agonists. They include semaglutide (Wegovy), liraglutide (Saxenda), and tirzepatide (Zepbound).

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

In the glittering world of celebrity-endorsed weight loss transformations and viral before-and-after photos, a darker narrative is emerging from the shadows ...

Eli Lilly and Company posted a surge in fourth-quarter revenues on Thursday, fuelled by strong demand for its blockbuster diabetes and weight-loss drugs.

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Studies have suggested that GLP-1RAs may show promise for a host of conditions, from alcohol use disorder to Parkinson’s. But ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.